Piperacillin/tazobactam
In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa Following Treatment-Emergent Resistance to Ceftolozane-Tazobactam.
Tazobactam
Association Between Minimum Inhibitory Concentration, Beta-Lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study.
Ceftolozane-Tazobactam Compared With Levofloxacin in the Treatment of Complicated Urinary-Tract Infections, Including Pyelonephritis: A Randomised, Double-Blind, Phase 3 Trial (ASPECT-cUTI)
Ceftolozane/tazobactam/Piperacillin/tazobactam
Piperacillin-Tazobactam for Pseudomonas aeruginosa Infection: Clinical Implications of an Extended-Infusion Dosing Strategy.
Ertapenem Versus Piperacillin/Tazobactam for Diabetic Foot Infections (SIDESTEP): Prospective, Randomised, Controlled, Double-Blinded, Multicentre Trial